• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

FDA approves new drug application for Pliaglis

The Food and Drug Administration has approved a supplemental new drug application for Pliaglis (lidocaine 7 percent, tetracaine 7 percent), a topical anesthetic cream.

Related Videos
3 experts are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Defining Treatment Options for Managing Chronic Atopic Dermatitis: Part 3
November 26th 2024

Defining Treatment Options for Managing Chronic Atopic Dermatitis: Part 3

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Conference Recap: 2024 Society of Dermatology Physician Associates Fall Dermatology Conference
November 25th 2024

Conference Recap: 2024 Society of Dermatology Physician Associates Fall Dermatology Conference

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

New Algorithm Proposes Targeted Lipase Monitoring for Pancreatic Adverse Events In Melanoma
November 25th 2024

New Algorithm Proposes Targeted Lipase Monitoring for Pancreatic Adverse Events In Melanoma

Heart Transplant Recipients are More Susceptible to Skin Cancer
November 25th 2024

Heart Transplant Recipients are More Susceptible to Skin Cancer

© 2024 MJH Life Sciences

All rights reserved.